image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.3553
-5.19 %
$ 9.69 M
Market Cap
-0.13
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one COSM stock under the worst case scenario is HIDDEN Compared to the current market price of 0.355 USD, Cosmos Health Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one COSM stock under the base case scenario is HIDDEN Compared to the current market price of 0.355 USD, Cosmos Health Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one COSM stock under the best case scenario is HIDDEN Compared to the current market price of 0.355 USD, Cosmos Health Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart COSM

image
$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
54.4 M REVENUE
1.97%
-15.5 M OPERATING INCOME
28.80%
-16.2 M NET INCOME
12.73%
-7.72 M OPERATING CASH FLOW
50.65%
-798 K INVESTING CASH FLOW
94.20%
5.05 M FINANCING CASH FLOW
-60.24%
12.4 M REVENUE
-6.02%
-2.24 M OPERATING INCOME
10.48%
-2.18 M NET INCOME
15.76%
740 K OPERATING CASH FLOW
161.09%
-35.4 K INVESTING CASH FLOW
-30.56%
2.68 M FINANCING CASH FLOW
396.60%
Balance Sheet Cosmos Health Inc.
image
Current Assets 25.5 M
Cash & Short-Term Investments 336 K
Receivables 13.5 M
Other Current Assets 11.6 M
Non-Current Assets 28.9 M
Long-Term Investments 0
PP&E 10.4 M
Other Non-Current Assets 18.5 M
24.82 %21.44 %19.15 %33.97 %Total Assets$54.3m
Current Liabilities 25.8 M
Accounts Payable 0
Short-Term Debt 2.77 M
Other Current Liabilities 23 M
Non-Current Liabilities 4.02 M
Long-Term Debt 2.06 M
Other Non-Current Liabilities 1.96 M
9.29 %77.20 %6.93 %6.58 %Total Liabilities$29.8m
EFFICIENCY
Earnings Waterfall Cosmos Health Inc.
image
Revenue 54.4 M
Cost Of Revenue 50.1 M
Gross Profit 4.31 M
Operating Expenses 19.9 M
Operating Income -15.5 M
Other Expenses 638 K
Net Income -16.2 M
60m60m50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)54m(50m)4m(20m)(16m)(638k)(16m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
7.92% GROSS MARGIN
7.92%
-28.56% OPERATING MARGIN
-28.56%
-41.12% NET MARGIN
-41.12%
-91.22% ROE
-91.22%
-41.20% ROA
-41.20%
-68.63% ROIC
-68.63%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cosmos Health Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -16.2 M
Depreciation & Amortization 1.25 M
Capital Expenditures -418 K
Stock-Based Compensation 1.69 M
Change in Working Capital 0
Others 5.54 M
Free Cash Flow -8.14 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cosmos Health Inc.
image
COSM has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Cosmos Health Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
518 K USD 1
0-3 MONTHS
539 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gains recognized in the prior year. globenewswire.com - 2 weeks ago
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L CHICAGO, April 09, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories (“Cana”), has completed the latest upgrades to its manufacturing capabilities and capacity, and has secured a long-term, five-year contract manufacturing agreement with Pharmex S.A. (“Pharmex”) for the annual production of 300,000 bottles of the antiseptic drug AMBITASOL 1L, totaling 1,500,000 units over the duration of the agreement. globenewswire.com - 3 weeks ago
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the launch of its Sky Premium Life food supplements brand in Albania, in partnership with Pharma Cell , a leading consumer health and medical supplement company that will serve as the distributor in the country. Cosmos Health has secured an initial annual order worth $300,000 and anticipates further scaling its collaboration with Pharma Cell over time. globenewswire.com - 3 weeks ago
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates CHICAGO, IL / ACCESS Newswire / February 26, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the addition of 60 new Stock Keeping Units (SKUs) to its Sky Premium Life nutraceutical brand. This expansion brings the total SKU count to over 150, broadening the product range to meet growing demand and evolving customer needs. accessnewswire.com - 2 months ago
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1 CHICAGO, IL / ACCESS Newswire / February 18, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. accessnewswire.com - 2 months ago
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market Finalizing scale-up production phase Engaging with Contract Research Organizations to complete the technical dossier Clinical trials expected to complete in late 2025 or early 2026 Potential classification as a Class III medical device Product launch expected in the first or second quarter of 2026 Further updates on progress to follow in the coming months CHICAGO, IL / ACCESS Newswire / February 11, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it is entering the final stage of development for CCX0722, its innovative weight management solution. The Company is currently finalizing the scale-up production phase, paving the way for human clinical trials and targeting a market launch in the first or second quarter of 2026. accessnewswire.com - 2 months ago
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of two new patent applications, covering groundbreaking developments in the treatment of glioma, an aggressive brain cancer, and hematologic malignancies, a complex group of blood cancers. The patent application for glioma has been filed under number N2039647, while the second application, numbered N2039645, focuses on hematologic malignancies, including multiple myeloma. accessnewswire.com - 2 months ago
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Dimitris Moraitis as Vice President of Strategy & Operations. Mr. Moraitis brings over 25 years of experience in strategic planning, operations, and business development within the pharmaceutical sector. accessnewswire.com - 2 months ago
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility CHICAGO, IL / ACCESS Newswire / February 7, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories ("Cana"), has entered into a new long-term ten-year contract manufacturing agreement with Provident Pharmaceuticals ("Provident"), a specialty pharmaceutical company, to produce four pharmaceutical products. These include Miorelique®, BE Union F.C. accessnewswire.com - 2 months ago
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar CHICAGO, IL / ACCESS Newswire / February 6, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an initial purchase order of $578,460 from Al Rabwa International Services and Trading ("Al Rabwa") for its Sky Premium Life® food supplement products in Qatar. The initial purchase order covers 35 of the Company's 79 SKUs. accessnewswire.com - 2 months ago
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market CHICAGO, IL / ACCESS Newswire / February 5, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a patent application for multiple sclerosis (MS), a disabling autoimmune disorder affecting millions worldwide. The patent application, filed under Application Number N2039644, represents a significant step forward in the Company's intellectual property strategy. accessnewswire.com - 2 months ago
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow CHICAGO, IL / ACCESS Newswire / January 28, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that, on January 27, 2025, its wholly owned subsidiary, CosmoFarm S.A. (the "Issuer" or "CosmoFarm"), entered into an agreement with a European bank to issue a €2,200,000 (approximately $2,293,830) secured bond (the "Loan"). accessnewswire.com - 3 months ago
8. Profile Summary

Cosmos Health Inc. COSM

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 9.69 M
Dividend Yield 0.00%
Description Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Contact 141 West Jackson Boulevard, Chicago, IL, 60604 https://www.cosmosholdingsinc.com
IPO Date July 23, 2010
Employees 149
Officers Prof. Dimitrios Trafalis Head of Oncology Mr. Georgios Terzis Chief Financial Officer Mr. Nikolaos Bardakis Chief Operating Officer Mr. Grigorios Siokas Chairman & Chief Executive Officer Mr. Demetrios G. Demetriades Secretary & Independent Director